Pharmaceutical Formulation Intermediates

Aprepitant Pellets 40.0% – Ready to Fill Into Capsules (Dose: 40 mg, 80 mg, or 125 mg)

• Matches with the innovator product in terms of the dissolution profile
• Conducted and cleared multimedia dissolution studies against the innovator product
• Offers a non-infringing product
• Do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets

Azithromycin Pellets/Powder 7.5%, 20%, 40% – Suitable for Capsules, Tablets, Suspension

• The objective of developing Azithromycin taste masked micro pellets (Multiple unit particulate system i.e. MUPS) by aqueous technology is to fill the micro pellets in to capsule, are compressed into tablet and also are constituted to make the oral suspension. MUPS has distinct advantages over single unit system such as multiple unit particles get distributed throughout the Gl tract thereby avoiding localized accumulation. Micro pellets developed by aqueous technology have also advantage of avoiding the use of organic solvents.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Brinzolamide Opthalmic Nano Suspension 1% W/V – Suitable for Suspension (Dose: 10 mg/ml)

• MKPPL developed a Nano particle based matrix which can deliver hydrophilic as well as hydrophobic drugs using a combination of hydrophilic and hydrophobic excipients as a clear solution. This cogent use of excipients ensures that the drug is absorbed optimally and the Nano particles ensure that the drug penetrates not only through the hydrophobic and hydrophilic channels but also through the OraSerrata which protects the eye from any foreign body entering the optical cavity.
• The formulation is in form of a clear solution and is available in the same concentration as the innovator i.e. 10 mg/ml.  The product can be offered as a solution that can be sterile filtered and filled.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Budesonide Pellets 0.8% -Available as Nano solution/Soft Mist & Ready to fill in Capsules.

• Release pattern compared with innovator
• MKPPL have entrapped 5 mg of drug in 1 ml of the nanoparticle formulation, whereas in the innovator formulation 0.25 mg is dispersed in 2 ml.
• MKPPL also standardized bud clear suspension (5mg/ml) which is 10 times the concentration of the innovator.
• Stability proves that the nanoparticles are stable and could be optimized.
• The release extends up to 24 hours to reach 100%.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Clarithromycin Taste Masked Granules 27.5%, 30%, 33%, 42%, 43.75% – Suitable for Capsules, Tablets, Suspensions (DOSE: 125 mg, 250 mg, 500 mg)

Clarithromycin is used to treat a wide variety of bacterial infections including the one’s caused by H. PYLORI. This medication can also be used in combination with anti-ulcer medications to treat certain types of stomach ulcers. It may also be used to prevent certain bacterial infections.

• Murli Krishna Pharma Pvt. Ltd. is a leading global PFI manufacturer and supplier for Clarithromycin PFI as granules.
• The process of Manufacturing Clarithromycin Taste Masked Pellets of MKPPL is completely aqueous based. No solvent has been used in any stage of manufacturing process. This process effectively masks the taste of the drug without compromising the dissolution rate.
• We offer development services if different formulation/dosage/strength are required.
• Complete technical package for registrations in all regulated/semi regulated markets are available
• Products protected by ongoing Patents are not offered by MKPPL.

Dabigatran Etexilate (DE) is a potent, synthetic, non-peptide competitive, rapidly acting oral direct thrombin inhibitor (oral DTI). It is an anticoagulant medication which can be taken by mouth. It is used as an alternative to warfarin.

Dabigatran Etexilate (DE) is the oral pro-drug of the active moiety dabigatran (DAB) and does not possess anticoagulant activity. The pro-drug dabigatran etexilate is used in its salt form dabigatran etexilate mesilate (DEM). That specifically and reversibly inhibits thrombin, the final enzyme in the coagulation cascade. The granted indication is primary prevention of venous thromboembolism (VTE) in patients undergoing elective major orthopedic surgery (MOS). It is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Dexlansoprazole DDR Pellets 17%, 20%, 22.5%, 23% – Suitable for Capsules (Dose: 30 mg, 60 mg)

The pharmaceutical form of dexlansoprazole is based on the unique technology of modified dual release. The active ingredient is released in two phases at different pH values and with a time interval. Consequently, the drug achieves two peak concentrations in the blood, and the total serum concentration of dexlansoprazole is three times higher.

• MKPPL has developed Dexlansoprazole pellets by aqueous technology to match the dissolution profile of Dexlansoprazole Pellets with Innovator.
• The product developed is comparable with innovator with respect to dissolution profile of the marketed product.
• We offer development services if different formulations/dosages/strengths are required
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.